These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35766874)

  • 1. Ciclosporin A Cationic Emulsion 0.1% for the Management of Dry Eye Disease: Facts That Matter for Eye-Care Providers.
    Labetoulle M; Leonardi A; Pisella PJ; Baudouin C
    Ocul Immunol Inflamm; 2023 Oct; 31(8):1707-1715. PubMed ID: 35766874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical cyclosporine A therapy for dry eye syndrome.
    de Paiva CS; Pflugfelder SC; Ng SM; Akpek EK
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD010051. PubMed ID: 31517988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
    Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
    Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
    Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
    Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keratitis in Dry Eye Disease and Topical Ciclosporin A.
    Leonardi A; Flamion B; Baudouin C
    Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical corticosteroids for dry eye.
    Liu SH; Saldanha IJ; Abraham AG; Rittiphairoj T; Hauswirth S; Gregory D; Ifantides C; Li T
    Cochrane Database Syst Rev; 2022 Oct; 10(10):CD015070. PubMed ID: 36269562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
    Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
    Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease.
    Sacchetti M; Mantelli F; Lambiase A; Mastropasqua A; Merlo D; Bonini S
    Br J Ophthalmol; 2014 Aug; 98(8):1016-22. PubMed ID: 24344232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease.
    Hoy SM
    Drugs; 2017 Nov; 77(17):1909-1916. PubMed ID: 29110189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
    Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
    Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine Anionic and Cationic Ophthalmic Emulsions in Dry Eye Disease: A Literature Review.
    Tong L; Sun CC; Yoon KC; Lim Bon Siong R; Puangsricharern V; Baudouin C
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1606-1615. PubMed ID: 32469256
    [No Abstract]   [Full Text] [Related]  

  • 14. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
    Periman LM; Perez VL; Saban DR; Lin MC; Neri P
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):137-146. PubMed ID: 32175799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
    Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
    Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease.
    Boboridis KG; Konstas AGP
    Expert Opin Pharmacother; 2018 Jun; 19(9):1027-1039. PubMed ID: 29847195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic Emulsion-Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease.
    Daull P; Amrane M; Ismail D; Georgiev G; Cwiklik L; Baudouin C; Leonardi A; Garhofer G; Garrigue JS
    J Ocul Pharmacol Ther; 2020; 36(6):355-365. PubMed ID: 32493105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye.
    Daull P; Nagano T; Gros E; Feraille L; Barabino S; Garrigue JS
    Curr Eye Res; 2021 Aug; 46(8):1096-1104. PubMed ID: 33588656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.
    Barabino S; Benitez-Del-Castillo JM; Fuchsluger T; Labetoulle M; Malachkova N; Meloni M; Utheim TP; Rolando M
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8642-8652. PubMed ID: 32964952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.